Ranbaxy Laboratories Limited (Ranbaxy) today announced the launch of its protein supplement under the brand name, ‘Revitalite’, marking its entry into the protein supplements market. Revitalite is unique in its category as it offers the highest quantity and quality of protein in each serving when compared with existing brands. Revitalite is similar to the world’s largest selling soy protein formulation and it comes at an affordable price. It can be easily mixed with favourite foods and beverages providing variety and choice to consumers.
To start with, Revitalite, marketed by Ranbaxy’s Global Consumer Healthcare division, has been introduced in Delhi, Mumbai, Chennai, Kolkata, Bangalore, Hyderabad, Lucknow, Kanpur, Varanasi, Patna, Jalandhar, Jaipur and Cochin. The product will be available through leading Chemists. It will be introduced in other urban markets of India, in a phased manner.
Commenting on the launch of the product, Mr. Atul Sobti, CEO & MD, Ranbaxy, said, “Ranbaxy has entered the high quality protein supplements market, keeping in mind the growing demand for this category. Our product, Revitalite, comes at an affordable price, and is an excellent option for the entire family. It will certainly address the problem of protein deficiency that impacts all age groups in our country.”
The protein supplements market in India is growing at 6%, and is currently valued at Rs. 252 Crores annually (ORG-IMS MAT June 2009).
Ranbaxy is already a key player in the Nutritional supplement market through its brand Revital. The launch of Revitalite further strengthens the Company’s position in this segment, that continues to exhibit strong growth.
Ranbaxy Global Consumer Healthcare (RGCH) was established in October 2002 with the objective of promoting consumer healthcare brands. Today it has some of the top selling brands in the country in this segment. The major brands from RGCH include Revital (Nutritional supplement) Volini (pain relieving Gel), Chericof (Cough Syrup) & Pepfiz (Digestive).
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.
